Clinical Trial: Safety and Efficacy of the Bispecific T-Cell Engager (BiTE) in Kidney Transplant Recipients With Chronic Active Antibody-Mediated Rejection

U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07689578) titled 'Safety and Efficacy of the Bispecific T-Cell Engager (BiTE) in Kidney Transplant Recipients With Chronic Active Antibody-Mediated Rejection' on June 24.

Brief Summary: This clinical trial aims to determine whether a bispecific T-cell engager (BiTE) targeting BCMAxCD3 effectively treats chronic active antibody-mediated rejection (cAMR) in kidney transplant recipients. The study also investigates the safety of BiTE in this patient population.

The main questions it aims to answer are:

1. Is BiTE safe and tolerable in kidney transplant recipients with cAMR?

2. Can BiTE improve cAMR? (i.e., can it reduce donor-specific antibody levels,...